Neuland Laboratories Limited DCF Valuation
NEULANDLAB · Healthcare · Current price ₹20,135
Neuland Laboratories Limited cash-flow valuation
Our discounted cash flow (2-stage) values Neuland Laboratories Limited at ₹2,481 per share. implied value is <0.2× the price (likely a data error). A discounted cash flow is only as good as the cash-flow path it assumes, so the assumptions behind it are listed in full below.
Try your own assumptions
Prefer to build the discounted cash flow yourself? The DCF calculator below opens pre-filled with Neuland Laboratories Limited's reported free cash flow, net debt and share count, so you can set your own growth and discount rate.
How we got this fair value
Every number below is part of the same estimate for Neuland Laboratories Limited. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹18,248 – ₹22,303
Why this method for this business
Relative P/E is appropriate for a pharmaceutical company with a durable moat and strong earnings power. DCF is used to capture the intrinsic value of the business, given its stable cash flows and strong capital allocation.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
implied value is <0.2× the price (likely a data error)
- ev_ebitda is not used due to lack of reliable EV data for peer comparison
- dcf is not the primary model due to the high sensitivity of the terminal growth rate and the need for a more stable multiple for a pharmaceutical company
What was missing
- Lack of detailed information on capital expenditures and R&D spending
- Limited analyst coverage for precise forward EPS estimates
What drives it
15 inputs, grouped by how strong each claim is
- Sector-median P/E
- 35.22×
- Peers used
- 39
- EPS (TTM)
- 387.97 ₹/share
- Own-history median P/E
- 27.03×
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Term: quality
- -3.2%
- Term: growth
- +40.0%
- Term: capital_allocation
- +9.6%
- Term: financial_strength
- +6.2%
- Term: history
- -7.0%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
quality 49/100 (weak/erratic returns) → discount
durable ~26% CAGR (ROCE 16% > hurdle) → premium
capital allocation: rising ROCE funded by strong FCF → premium
financial strength: low leverage (D/E 0.2) → mild premium
history: market paid -23% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- +48.4%
- Fair-multiple confidence
- 82%
- Fair P/E
- 52.26×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Neuland Laboratories Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on Neuland Laboratories Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.